Aurinia Pharmaceuticals Inc. Earnings Per Share (Basic)
Aurinia Pharmaceuticals Inc. (AUPH) reported Earnings Per Share (Basic) of $0.29 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. earnings per share, basic for the quarter ending 2026-06-30 was $0.29, a 81.25% increase year-over-year.
- Aurinia Pharmaceuticals Inc. earnings per share, basic for the quarter ending 2026-03-31 was $0.26, a 52.94% increase year-over-year.
- Aurinia Pharmaceuticals Inc. earnings per share, basic for the quarter ending 2025-12-31 was $1.60, a 15900.00% increase year-over-year.
- Aurinia Pharmaceuticals Inc. earnings per share, basic for the quarter ending 2025-09-30 was $0.24, a 140.00% increase year-over-year.
- Aurinia Pharmaceuticals Inc. earnings per share, basic for fiscal 2025 was $2.14, a 5250.00% increase from fiscal 2024.
- Aurinia Pharmaceuticals Inc. earnings per share, basic for fiscal 2024 was $0.04.
- Aurinia Pharmaceuticals Inc. earnings per share, basic for fiscal 2023 was -$0.54.
- Aurinia Pharmaceuticals Inc. earnings per share, basic for fiscal 2022 was -$0.76.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.29 10-Q · filed 2026-08-06 | $0.55 10-Q · filed 2026-08-06 | $2.15 derived: net income ÷ weighted average shares · filed 2026-08-06 | $2.39 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | $0.26 10-Q · filed 2026-05-07 | $1.85 derived: net income ÷ weighted average shares · filed 2026-08-06 | $2.10 derived: net income ÷ weighted average shares · filed 2026-08-06 | $2.25 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | $1.60 10-K · filed 2026-02-26 | $1.84 derived: net income ÷ weighted average shares · filed 2026-02-26 | $1.99 derived: net income ÷ weighted average shares · filed 2026-08-06 | $2.14 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.24 10-K · filed 2026-02-26 | $0.40 derived: net income ÷ weighted average shares · filed 2026-08-06 | $0.57 10-Q · filed 2025-11-04 | $0.57 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | $0.16 10-Q · filed 2026-08-06 | $0.33 10-Q · filed 2026-08-06 | $0.33 derived: net income ÷ weighted average shares · filed 2026-08-06 | $0.43 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | $0.17 10-Q · filed 2026-05-07 | $0.18 derived: net income ÷ weighted average shares · filed 2026-08-06 | $0.28 derived: net income ÷ weighted average shares · filed 2026-08-06 | $0.28 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2024-12-31 | $0.01 10-K · filed 2026-02-26 | $0.11 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.12 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.04 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.10 10-K · filed 2026-02-26 | $0.11 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.03 10-Q · filed 2025-11-04 | -$0.16 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2024-06-30 | $0.01 10-K · filed 2026-02-26 | -$0.07 10-Q · filed 2025-07-31 | -$0.26 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.35 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2024-03-31 | -$0.07 10-K · filed 2026-02-26 | -$0.26 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.36 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.44 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2023-12-31 | -$0.19 10-K · filed 2025-02-27 | -$0.28 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.36 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.54 10-K · filed 2026-02-26 |
| 2023-09-30 | -$0.09 10-K · filed 2025-02-27 | -$0.17 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.36 10-Q · filed 2024-11-07 | -$0.54 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2023-06-30 | -$0.08 10-K · filed 2025-02-27 | -$0.26 10-Q · filed 2024-08-01 | -$0.45 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.51 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2023-03-31 | -$0.18 10-K · filed 2025-02-27 | -$0.37 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.43 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.68 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2022-12-31 | -$0.18 10-K · filed 2024-02-15 | -$0.25 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.50 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.76 10-K · filed 2025-02-27 |
| 2022-09-30 | -$0.06 10-K · filed 2024-02-15 | -$0.31 derived: net income ÷ weighted average shares · filed 2024-02-15 | -$0.58 10-Q · filed 2023-11-02 | -$0.83 derived: net income ÷ weighted average shares · filed 2024-02-15 |
| 2022-06-30 | -$0.25 10-K · filed 2024-02-15 | -$0.52 10-Q · filed 2023-08-03 | -$0.77 derived: net income ÷ weighted average shares · filed 2024-02-15 | -$1.15 derived: net income ÷ weighted average shares · filed 2024-02-15 |
| 2022-03-31 | -$0.27 10-K · filed 2024-02-15 | -$0.52 derived: net income ÷ weighted average shares · filed 2024-02-15 | -$0.90 derived: net income ÷ weighted average shares · filed 2024-02-15 | -$1.27 derived: net income ÷ weighted average shares · filed 2024-02-15 |
| 2021-12-31 | -$0.25 10-K · filed 2023-02-28 | -$0.64 derived: net income ÷ weighted average shares · filed 2024-02-15 | -$1.00 derived: net income ÷ weighted average shares · filed 2024-02-15 | -$1.40 10-K · filed 2024-02-15 |
| 2021-09-30 | -$0.39 10-K · filed 2023-02-28 | -$0.76 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$1.15 10-Q · filed 2022-11-03 | -$1.22 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2021-06-30 | -$0.37 10-K · filed 2023-02-28 | -$0.76 10-Q · filed 2022-08-04 | -$0.83 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$1.17 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2021-03-31 | -$0.40 10-K · filed 2023-02-28 | -$0.46 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$0.80 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$1.04 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2020-12-31 | -$0.06 10-K · filed 2022-02-28 | -$0.40 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$0.64 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$0.87 10-K · filed 2023-02-28 |
| 2020-09-30 | -$0.34 10-K · filed 2022-02-28 | -$0.58 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$0.82 10-Q · filed 2021-11-03 | |
| 2020-06-30 | -$0.24 10-K · filed 2022-02-28 | -$0.47 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | -$0.23 10-K · filed 2022-02-28 | |||
| 2019-12-31 | -$0.95 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |